- Home
- BMRC vs DMAC Comparison
BMRC vs DMAC Comparison
Compare BMRC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- DMAC
- Stock Information
- Founded
- BMRC 1989
- DMAC 2000
- Country
- BMRC United States
- DMAC United States
- Employees
- BMRC N/A
- DMAC N/A
- Industry
- BMRC Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- BMRC Finance
- DMAC Health Care
- Exchange
- BMRC Nasdaq
- DMAC Nasdaq
- Market Cap
- BMRC 384.1M
- DMAC 310.1M
- IPO Year
- BMRC N/A
- DMAC N/A
- Fundamental
- Price
- BMRC $22.71
- DMAC $6.58
- Analyst Decision
- BMRC Buy
- DMAC Strong Buy
- Analyst Count
- BMRC 4
- DMAC 3
- Target Price
- BMRC $26.25
- DMAC $12.33
- AVG Volume (30 Days)
- BMRC 67.1K
- DMAC 253.9K
- Earning Date
- BMRC 10-27-2025
- DMAC 11-12-2025
- Dividend Yield
- BMRC 4.40%
- DMAC N/A
- EPS Growth
- BMRC N/A
- DMAC N/A
- EPS
- BMRC 0.43
- DMAC N/A
- Revenue
- BMRC $93,409,000.00
- DMAC N/A
- Revenue This Year
- BMRC $61.22
- DMAC N/A
- Revenue Next Year
- BMRC $12.21
- DMAC N/A
- P/E Ratio
- BMRC $52.53
- DMAC N/A
- Revenue Growth
- BMRC 59.35
- DMAC N/A
- 52 Week Low
- BMRC $19.14
- DMAC $3.19
- 52 Week High
- BMRC $27.11
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- BMRC 38.81
- DMAC 46.80
- Support Level
- BMRC $22.50
- DMAC $6.56
- Resistance Level
- BMRC $24.42
- DMAC $7.24
- Average True Range (ATR)
- BMRC 0.62
- DMAC 0.32
- MACD
- BMRC -0.20
- DMAC -0.08
- Stochastic Oscillator
- BMRC 9.85
- DMAC 18.34
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.